Becton Dickinson and (BDX)
Becton Dickinson and (BDX) Stock Price, Analysis & Data
| Bid | 179.82 |
| Market Cap | 49.96B |
| Revenue (ttm) | 22.48B |
| Net Income (ttm) | 1.65B |
| Beta | 0.26 |
| EPS (ttm) | 5.79 |
| PE Ratio (ttm) | 31.46 |
| Forward PE | 13.78 |
| P/B (ttm) | 2.05 |
| P/S (ttm) | 2.22 |
| Earnings Date | Nov 5, 2026 |
| Ask | 186 |
| Volume | 712,383 |
| Avg. Volume (20D) | 2,380,147 |
| Open | 182.12 |
| Previous Close | 181.97 |
| Day's Range | 181.26 - 183.82 |
| 52-Week Range | 127.59 - 187.35 |
| Analyst | Buy |
| Price Target | 192.5 (4.96%) |
| Dividends | $4.2 (2.29%) |
| Ex-Dividend Date | Sep 9, 2026 |
About BDX
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and ad...
Financial Performance
In 2025, Becton Dickinson and's revenue was 21.84B, an increase of 8.24% compared to the previous year's 20.18B. Earnings were 1.68B, a decrease of -1.58%.
Financial StatementsAnalyst Forecast
According to 12 analyst ratings, the average rating for BDX stock is "Buy". The 12-month stock price forecast is 192.5, which is upside of 4.96% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
